Design Therapeutics (DSGN) Interest & Investment Income (2024 - 2026)
Design Therapeutics recorded quarterly Interest & Investment Income of $2.1 million in Q1 2026, down 4.7% quarter-over-quarter from $2.2 million in Q4 2025, and down 23.42% year-over-year from $2.7 million in Q1 2025.
Design Therapeutics' Interest & Investment Income history runs 3 years deep, the most recent figure standing at $2.1 million for Q1 2026.
- In Q1 2026, Interest & Investment Income fell 23.42% year-over-year to $2.1 million; the TTM figure through Mar 2026 stood at $9.0 million (down 25.9% YoY), while the FY2025 annual figure was $9.7 million, down 24.38% from the prior year.
- Interest & Investment Income came in at $2.1 million for Q1 2026 at Design Therapeutics, down from $2.2 million in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $3.3 million in Q1 2024 to a low of $2.1 million in Q1 2026.
- A 3-year average of $2.7 million and a median of $2.7 million in 2025 frame the typical range for Interest & Investment Income.
- On a YoY basis, Interest & Investment Income climbed as much as 17.97% in 2025 and fell as far as 28.62% in 2025.
- Design Therapeutics' Interest & Investment Income stood at $3.0 million in 2024, then retreated by 28.62% to $2.2 million in 2025, then dropped by 4.7% to $2.1 million in 2026.
- According to Business Quant data, Interest & Investment Income over the past three periods registered $2.1 million, $2.2 million, and $2.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 7.90 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 114.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 305,000.00 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 26.60 Mn |
| 10 | Design Therapeutics | 640.15 Mn | 417.32 Mn | - | 2.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.07 Mn |
| Dec 31, 2025 | 2.17 Mn |
| Sep 30, 2025 | 2.31 Mn |
| Jun 30, 2025 | 2.49 Mn |
| Mar 31, 2025 | 2.70 Mn |
| Dec 31, 2024 | 3.04 Mn |
| Sep 30, 2024 | 3.21 Mn |
| Jun 30, 2024 | 3.25 Mn |
| Mar 31, 2024 | 3.30 Mn |